Tworoger Shelley S, Lee I-Min, Buring Julie E, Pollak Michael N, Hankinson Susan E
Channing Laboratory, Department of Medicine, Harvard School of Public Health, 3rd Floor, 181 Longwood Avenue, Boston, MA 02115, USA.
Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1691-5. doi: 10.1158/1055-9965.EPI-07-0319.
Insulin-like growth factor (IGF)-related hormones and binding proteins (IGFBP) have been implicated in cancer risk. Specifically, two recent, small prospective studies reported a significant positive association between IGF-I and ovarian cancer risk among women diagnosed before age 55 years. Therefore, we examined whether plasma concentrations of IGF-I, IGFBP-3, and IGFBP-2 were associated with risk of epithelial ovarian cancer in a nested case-control study using data from three prospective cohorts: the Nurses' Health Study (NHS), NHSII, and the Women's Health Study (WHS). The present study had 222 cases (159 from NHS/NHSII and 63 from WHS) and 599 controls (matching ratio, 1:3 for NHS/NHSII and 1:2 for WHS). Women ranged in age from 34 to 73 years (mean, 56 years). The relative risk (RR) comparing the top versus bottom quartile of IGF-I was 0.56 (95% confidence interval, 0.32-0.97; P(trend) = 0.14). The risk did not differ by age at diagnosis (comparable RR for age <55 years at diagnosis, 0.70; RR for age >/=55 years at diagnosis, 0.52). We did not observe any association between IGFBP-3, IGFBP-2, and the ratio of IGF-I to either binding protein and ovarian cancer risk. Overall, our results do not support a positive association between IGF-related proteins and ovarian cancer risk. (Cancer Epidemiol Biomarkers Prev 2007;16(8):1691-5).
胰岛素样生长因子(IGF)相关激素和结合蛋白(IGFBP)与癌症风险有关。具体而言,最近两项小型前瞻性研究报告称,在55岁之前被诊断出的女性中,IGF-I与卵巢癌风险之间存在显著的正相关。因此,我们在一项巢式病例对照研究中,使用来自三项前瞻性队列研究(护士健康研究(NHS)、NHSII和女性健康研究(WHS))的数据,检验了血浆中IGF-I、IGFBP-3和IGFBP-2的浓度是否与上皮性卵巢癌风险相关。本研究有222例病例(159例来自NHS/NHSII,63例来自WHS)和599例对照(匹配比例,NHS/NHSII为1:3,WHS为1:2)。女性年龄范围为34至73岁(平均56岁)。比较IGF-I最高四分位数与最低四分位数的相对风险(RR)为0.56(95%置信区间,0.32 - 0.97;P趋势 = 0.14)。诊断时的年龄不同,风险无差异(诊断时年龄<55岁的可比RR为0.70;诊断时年龄≥55岁的RR为0.52)。我们未观察到IGFBP-3、IGFBP-2以及IGF-I与任一结合蛋白的比值和卵巢癌风险之间存在任何关联。总体而言,我们的结果不支持IGF相关蛋白与卵巢癌风险之间存在正相关。(《癌症流行病学、生物标志物与预防》2007年;16(8):1691 - 5)